Inventor · disambiguated record
Eugene Richard Hickey
Also filed as: HICKEY EUGENE · HICKEY EUGENE R · HICKEY EUGENE RICHARD
66 granted patents·19 pending applications·1,413 citations·filing 1998–2024
99Inventor score
Files withBOEHRINGER INGELHEIM PHARMA32BOEHRINGER INGELHEIM INT9PETRA PHARMA CORP8MORPHIC THERAPEUTIC INC6AERIE PHARMACEUTICALS INC4
Top patents by PatentIndex Score
85 records- 0198US6358945B1Compounds useful as anti-inflammatory agentsBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Mar 19, 2002·138 cites·26 claims
- 0297US7595397B2Compounds which modulate the CB2 receptorBOEHRINGER INGELHEIM INT·Filed 2006·Granted Sep 29, 2009·90 cites·4 claims
- 0396US8173638B2Compounds which modulate the CB2 receptorBERRY ANGELA·Filed 2007·Granted May 8, 2012·25 cites·8 claims
- 0496US6420364B1Compound useful as reversible inhibitors of cysteine proteasesBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Jul 16, 2002·59 cites·37 claims
- 0596US6319921B1Aromatic heterocyclic compound as antiinflammatory agentsBOERHRINGER INGELHEIM PHARMACEUTICALS INC·Filed 2000·Granted Nov 20, 2001·198 cites·19 claims
- 0695US8048899B2Compounds which selectively modulate the CB2 receptorBOEHRINGER INGELHEIM INT·Filed 2009·Granted Nov 1, 2011·40 cites·32 claims
- 0794US11739087B2Inhibiting (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2021·Granted Aug 29, 2023·5 cites·9 claims
- 0894US8809326B2Isoquinolinone Rho kinase inhibitorsBOSANAC TODD·Filed 2007·Granted Aug 19, 2014·40 cites·5 claims
- 0994US6492393B1Compounds useful as anti-inflammatory agentsBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Dec 10, 2002·70 cites·12 claims
- 1094US6080763AAromatic heterocyclic compounds and their use as anti-inflammatory agentsBOEHRINGER INGELHEIM PHARMA·Filed 1998·Granted Jun 27, 2000·128 cites·8 claims
- 1193US7935715B2Compounds which modulate the CB2 receptorBOEHRINGER INGELHEIM INT·Filed 2007·Granted May 3, 2011·34 cites·3 claims
- 1293US6297381B1Aromatic heterocyclic compounds as anti-inflammatory agentsBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Oct 2, 2001·55 cites·20 claims
- 1392US8362039B2Therapeutic uses of compounds which selectively modulate the CB2 receptorBOEHRINGER INGELHEIM INT·Filed 2011·Granted Jan 29, 2013·17 cites·20 claims
- 1492US7601714B2Pyrimidine derivatives useful as inhibitors of PKC-thetaBOEHRINGER INGELHEIM PHARMA·Filed 2005·Granted Oct 13, 2009·33 cites·9 claims
- 1592US6242453B1Polycyclo heterocyclic derivatives as antiinflammatory agentsBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Jun 5, 2001·53 cites·18 claims
- 1691US8349871B2Therapeutic uses of compounds which selectively modulate the CB2 receptorBOEHRINGER INGELHEIM INT·Filed 2011·Granted Jan 8, 2013·15 cites·6 claims
- 1790US11873295B2Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of diseasePETRA PHARMA CORP·Filed 2022·Granted Jan 16, 2024·3 cites·125 claims
- 1889US11370773B1Inhibiting human integrin (alpha-4) (beta-7)MORPHIC THERAPEUTIC INC·Filed 2021·Granted Jun 28, 2022·2 cites·24 claims
- 1988US8629157B2Pyrrolidine compounds which modulate the CB2 receptorBERRY ANGELA·Filed 2009·Granted Jan 14, 2014·14 cites·10 claims
- 2088US8299103B2Compounds which selectively modulate the CB2 receptorBARTOLOZZI ALESSANDRA·Filed 2010·Granted Oct 30, 2012·12 cites·15 claims
- 2188US8299111B2Compounds which modulate the CB2 receptorBERRY ANGELA·Filed 2010·Granted Oct 30, 2012·14 cites·9 claims
- 2288US6313117B1Succinate derivative compounds useful as cysteine protease inhibitorsBOEHRINGER INGELHEIM PHARMA·Filed 2000·Granted Nov 6, 2001·39 cites·27 claims
- 2387US6660732B2Compounds useful as anti-inflammatory agentsBOEHRINGER INGELHEIM PHARMA·Filed 2001·Granted Dec 9, 2003·24 cites·22 claims
- 2487US6656933B2Compounds useful as anti-inflammatory agentsBOEHRINGER INGELHEIM PHARMA·Filed 2001·Granted Dec 2, 2003·20 cites·8 claims
- 2587US6525052B2Compounds useful as reversible inhibitors of cysteine proteasesBOEHRINGER INGELHEIM PHARMA·Filed 2001·Granted Feb 25, 2003·17 cites·11 claims
- 2687US6432995B2Aromatic heterocyclic compounds and their use as anti-inflammatory agentsBOEHRINGER INGELHEIM PHARMA·Filed 2001·Granted Aug 13, 2002·15 cites·11 claims
- 2787US6333325B1Method of treating cytokine mediated diseases or conditionsBOEHRINGER INGELHEIM PHARMA·Filed 2001·Granted Dec 25, 2001·21 cites·6 claims
- 2886US8372874B2Compounds which selectively modulate the CB2 receptorBOEHRINGER INGELHEIM INT·Filed 2009·Granted Feb 12, 2013·6 cites·12 claims
- 2986US6228881B1Aromatic heterocyclic compounds and their use as anti-inflammatory agentsBOEHRINGER INGELHEIM PHARMA·Filed 1999·Granted May 8, 2001·32 cites·11 claims
- 3085US12459942B2Inhibiting (α-v)(β-6) integrinMORPHIC THERAPEUTIC INC·Filed 2024·Granted Nov 4, 2025·0 cites·18 claims
- 3185US6974870B2Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their usesBOEHRINGER INGELHEIM PHAMACEUT·Filed 2003·Granted Dec 13, 2005·23 cites·5 claims
- 3284US8093266B2Rho kinase inhibitorsDAHMANN GEORG·Filed 2008·Granted Jan 10, 2012·8 cites·11 claims
- 3383US7279472B2Compounds useful as reversible inhibitors of cysteine proteasesBOEHRINGER INGELHEIM PHARMA·Filed 2004·Granted Oct 9, 2007·10 cites·11 claims
- 3483US6476023B1Aromatic heterocyclic compounds as anti-inflammatory agentsBOEHRINGEN INGELHEIM PHARMACEU·Filed 2000·Granted Nov 5, 2002·24 cites·19 claims
- 3582US8383615B2Azetidine 2-carboxamide derivatives which modulate the CB2 receptorBOEHRINGER INGELHEIM INT·Filed 2010·Granted Feb 26, 2013·6 cites·17 claims
- 3682US6858623B2Compounds useful as reversible inhibitors of cysteine proteasesBOEHRINGER INGELHEIM PHARMA·Filed 2003·Granted Feb 22, 2005·9 cites·9 claims
- 3781US11649227B2Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of diseasePETRA PHARMA CORP·Filed 2021·Granted May 16, 2023·1 cites·20 claims
- 3881US11104661B1Inhibiting human integrin (α-4) (β-7)MORPHIC THERAPEUTIC INC·Filed 2020·Granted Aug 31, 2021·1 cites·24 claims
- 3981US8889670B2Heterocyclic compounds which modulate the CB2 receptorBARTOLOZZI ALESSANDRA·Filed 2010·Granted Nov 18, 2014·6 cites·13 claims
- 4081US8829034B2Compounds which modulate the CB2 receptorBERRY ANGELA·Filed 2011·Granted Sep 9, 2014·6 cites·9 claims
- 4181US6964956B2Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their usesBOEHRINGER INGELHEIM PHARMA·Filed 2003·Granted Nov 15, 2005·15 cites·6 claims
- 4280US8735430B2Compounds which selectively modulate the CB2 receptorBARTOLOZZI ALESSANDRA·Filed 2012·Granted May 27, 2014·6 cites·13 claims
- 4380US6720321B21,4-disubstituted benzo-fused cycloalkyl urea compoundsBOEHRINGER INGELHEIM PHARMA·Filed 2002·Granted Apr 13, 2004·14 cites·16 claims
- 4479US6982272B2Compounds useful as reversible inhibitors of cysteine proteasesBOEHRINGER INGELHEIM PHARMA·Filed 2003·Granted Jan 3, 2006·6 cites·5 claims
- 4578US11667651B2Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitorsHIBERCELL INC·Filed 2018·Granted Jun 6, 2023·1 cites·11 claims
- 4678US7405225B2Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their usesBOEHRINGER INGELHEIM PHARMA·Filed 2005·Granted Jul 29, 2008·3 cites·4 claims
- 4778US6506748B2Aromatic heterocyclic compounds as antiinflammatory agentsBOEHRINGER INGELHEIM PHARMA·Filed 2001·Granted Jan 14, 2003·7 cites·15 claims
- 4877US8957063B2Amine and ether compounds which modulate the CB2 receptorCIRILLO PIER FRANCESCO·Filed 2009·Granted Feb 17, 2015·6 cites·5 claims
- 4977US8846936B2Sulfonyl compounds which modulate the CB2 receptorHICKEY EUGENE RICHARD·Filed 2011·Granted Sep 30, 2014·6 cites·14 claims
- 5077US6649642B2Succinate derivative compounds useful as cysteine protease inhibitorsBOEHRINGER INGELHEIM PHARMA·Filed 2002·Granted Nov 18, 2003·7 cites·16 claims
Showing the top 50 of 85 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Eugene Richard Hickey files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →